Patents by Inventor Heidrun Engler

Heidrun Engler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8022044
    Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: September 20, 2011
    Assignee: Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Publication number: 20110104118
    Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
    Type: Application
    Filed: October 26, 2010
    Publication date: May 5, 2011
    Applicant: Canji, Inc.
    Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
  • Publication number: 20100028431
    Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
    Type: Application
    Filed: April 13, 2009
    Publication date: February 4, 2010
    Applicants: Canji Inc.,, Schering Corporation,
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Patent number: 7538093
    Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: May 26, 2009
    Assignees: Schering Corporation, Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Patent number: 7534769
    Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: May 19, 2009
    Assignees: Canji, Inc., Schering Corporation
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Publication number: 20090048148
    Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
    Type: Application
    Filed: March 28, 2008
    Publication date: February 19, 2009
    Applicant: Canji, Inc
    Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
  • Patent number: 7462351
    Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: December 9, 2008
    Assignees: Canji, Inc., Innovata Limited
    Inventors: Susan E. Conroy, Heidrun Engler, Daniel C. Maneval
  • Publication number: 20060199782
    Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
    Type: Application
    Filed: February 21, 2006
    Publication date: September 7, 2006
    Applicants: Canji, Inc., Schering Corporation
    Inventors: Heidrun Engler, Tattanahalli Nagabhushan, Stephen Youngster
  • Patent number: 7002027
    Abstract: The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for administration to any tissue or organ having an epithelial membrane. The delivery-enhancing agents include detergents, alcohols, surfactants and other molecules.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: February 21, 2006
    Assignees: Canji, Inc., Schering Corporation
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Publication number: 20050025742
    Abstract: Methods and pharmaceutical compositions for administering protein or gene therapy to tissues or organs having an epithelial cell layer are provided. A protein or nucleic acid encoding the protein is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the delivery of the interferon or nucleic acid to the cells of the target tissues or organs. The methods and combinations are particularly useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an alpha-interferon or a gene delivery system encoding the interferon and SYN3 or a SYN3 homolog or analog.
    Type: Application
    Filed: June 4, 2004
    Publication date: February 3, 2005
    Applicant: Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli Nagabhushan, Stephen Youngster, Robert Connor
  • Publication number: 20050014259
    Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
    Type: Application
    Filed: August 6, 2004
    Publication date: January 20, 2005
    Inventors: Susan Conroy, Heidrun Engler, Daniel Maneval
  • Publication number: 20040014709
    Abstract: Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.
    Type: Application
    Filed: June 4, 2003
    Publication date: January 22, 2004
    Applicant: Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Youngster
  • Publication number: 20030211598
    Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
    Type: Application
    Filed: June 3, 2003
    Publication date: November 13, 2003
    Applicant: CANJI, INC.
    Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
  • Publication number: 20020111502
    Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
    Type: Application
    Filed: January 22, 2002
    Publication date: August 15, 2002
    Applicant: Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Publication number: 20020081736
    Abstract: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
    Type: Application
    Filed: November 1, 2001
    Publication date: June 27, 2002
    Inventors: Susan E. Conroy, Heidrun Engler, Daniel C. Maneval
  • Patent number: 6392069
    Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: May 21, 2002
    Assignee: Canji, Inc.
    Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
  • Patent number: 6312681
    Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: November 6, 2001
    Assignee: Canji Incorporated
    Inventors: Heidrun Engler, Dan Maneval
  • Publication number: 20010006946
    Abstract: This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
    Type: Application
    Filed: July 8, 1998
    Publication date: July 5, 2001
    Inventors: HEIDRUN ENGLER, TATTANAHALLI L. NAGABHUSHAN
  • Patent number: 6165779
    Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: December 26, 2000
    Assignee: Canji, Inc.
    Inventors: Heidrun Engler, Bernard G. Huyghe, Daniel C. Maneval, Paul Shabram
  • Patent number: 5182294
    Abstract: A new imidazolyl propyl guanidine derivative corresponding to formula I ##STR1## is described, which is distinguished by a combination of particularly advantageous properties for the treatment of diseases of the heart and circulation.
    Type: Grant
    Filed: January 10, 1991
    Date of Patent: January 26, 1993
    Assignee: Heumann Pharma GmbH & Co.
    Inventors: Peter Morsdorf, Heidrun Engler, Helmut Schickaneder, Kurt-Henning Ahrens